Apimeds and MindWave Announce Merger, Integrating Biotech Growth with AI-Driven Digital Treasury Yield Generation Backed by $100M PIPE

MATAWAN, N.J.--(BUSINESS WIRE)--(NYSE American: APUS) Apimeds Pharmaceuticals US, Inc. ("Apimeds†), a clinical-stage biotechnology company that completed its IPO in May 2025, today announced that it has merged with MindWave Innovations Inc ("MindWave†; the transaction, the "Merger†). Today, Apimeds and MindWave signed the merger agreement (the "Merger Agreement†) outlining the terms of the Merger, thus paving the way for a dual-growth enterprise spanning advanced biotechnology and institutional. ...